Companies › Artiva Biotherapeutics
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Immunology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AlloNK Allogeneic non-genetically modified cord blood-derived NK cell therapy | – | Phase 2 | Refractory Rheumatoid Arthritis (RA) | Jan 2028 |
| AB-101 Allogeneic natural killer (NK) cell therapy | – | Phase 1 | Lupus Nephritis - WHO Class III | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06265220 | AB-101 | Phase 1 | Lupus Nephritis - WHO Class III | Immunology | Aug 2027 |
| NCT06991114 | AlloNK | Phase 2 | Refractory Rheumatoid Arthritis (RA) | Immunology | Jan 2028 |
Cash and short-term investments of $319m on 2026-09-30; operating cash outflow about $94m a year; runway about 41 months at that burn, to Feb 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Cellcolabs Clinical SPV EHL Bio Nature Cell Throne Biotechnologies Xentria
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.